A literatur survey concludes that the efficacy of recombinant activated factor VII administered by continuous infusion (rFVIIa CI) in patients with congenital hemophilia with inhibitors or congenital ...

‌Factor VII deficiency is a rare genetic disorder. It occurs when your body can’t produce enough clotting factor VII, which helps in healing wounds. It can be hereditary or be caused by an underlying ...

NovoSeven RT is a prescription drug used to treat certain blood clotting disorders, including hemophilia. The drug is given as an intravenous (IV) infusion, which is an injection into a vein over a ...

Hematology researchers have further refined how a treatment currently used on an urgent basis to control bleeding in hemophilia patients holds promise as a preventive treatment as well. A study in ...

The use of factor VIIa (recombinant) as a hemostatic agent is attractive for several reasons. Because it is cloned and expressed in baby hamster kidney cells and purified without use of human serum or ...

Villar and colleagues [10] determined the pharmacokinetics of factor VIIa (recombinant) in 12 children (age 2–12 years) and 6 adults with hemophilia A, with and without inhibitors to factor VIII, ...

(RTTNews) - The board of Sino Biopharmaceutical (SBMFF) announced that the Group's self-developed Recombinant Human Coagulation Factor VIIa N01 for Injection, with brand name: Anqixin - has been ...

Hemophilia A and B coagulation defects, which are caused by deficiencies of Factor VIII and Factor IX, respectively, can be bypassed by administration of recombinant Factor VIIa. However, the short ...

PCI-27483 selectively inhibits Factor VIIa when it is complexed with tissue factor. "We're encouraged by the promising preclinical results with PCI-27483 as we broaden our portfolio of product ...

Hematology researchers have further refined how a treatment currently used on an urgent basis to control bleeding in hemophilia patients holds promise as a preventive treatment as well. A study in ...